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ORIGINAL ARTICLE
It is well known that inflammation plays pivotal
roles in the pathogenesis of atherosclerosis.1,2 C-
reactive protein (CRP), an acute-phase reactant
indicating active inflammation has been shown
to correlate with stable angina pectoris,3 acute
coronary syndrome,4 stroke,5,6 and peripheral
vascular disease.7 Epidemiologic surveys reveal
that elevated high-sensitivity CRP concentrations
are associated with an increased risk of future
cardiovascular events among healthy men8,9 and
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women.10 CRP has also been shown to impair
endothelium-dependent vasodilation via the nitric
oxide pathway,11–13 impair angiogenic function
and attenuate survival of endothelial progenitor
cells,14,15 and induce proinflammatory and pro-
atherogenic effects in several types of cells.16–18
More and more evidence indicate the direct path-
ogenic effects of CRP in atherosclerosis, of which
coronary artery disease (CAD) is the most critical
disease.
The interplays between genetic and environ-
mental factors are important in the phenotype
development of complex trait diseases, such as
CAD. Several single nucleotide polymorphisms
of the CRP gene have been demonstrated to affect
plasma CRP concentration, such as +1059 G > C
and +1444 C > T in exon 2 and intronic T > A
polymorphisms.19,20
Prior studies showed that 1059 G > C was as-
sociated with plasma concentrations of CRP.19
The relationship persisted after adjustment for
nongenetic confounders (e.g., age, sex and body
mass index [BMI] etc.) and was present in sub-
jects with and without prevalent coronary dis-
ease in the Caucasian population.21 Another study
showed that the CRP 1059 G > C polymorphism
was neither associated with future myocardial in-
farction (MI) and stroke, nor with post-angioplasty
restenosis.22 Therefore, its correlation with the
pathogenesis of CAD remains unknown. We thus
intended to study the effect of this polymorphism
on the risk of CAD in the Chinese population in
Taiwan.
Materials and Methods
Study population
We recruited 536 patients undergoing coronary
angiography at the National Taiwan University
Hospital from April 2002 to October 2003. They
consisted of 365 patients with CAD and 171 con-
trols with patent coronaries, matched for sex 
and age in approximately 2:1 ratio. All of them
are Chinese who mainly reside in Taipei and the
northern part of Taiwan. Exclusion criteria included
rheumatologic disorders, malignancy, active in-
fection and overt heart failure. During hospitaliza-
tion, all participants had a record on age, sex, BMI,
classical risk factors of atherosclerosis, including
diabetes, hypertension, smoking habit, hypercho-
lesterolemia (total cholesterol ≥200 mg/dL and/or
LDL-cholesterol ≥ 160 mg/dL) and hypertriglycer-
idemia (triglyceride ≥ 200 mg/dL). Baseline lab-
oratory measurements included complete blood
count, blood sugar level, biochemistry and lipid
profiles. This study was approved by the hospital's
ethics committee, and informed consent was 
obtained from all participants.
Phenotype definition in case control studies
CAD was defined as the presence of at least one
significant coronary artery stenosis of more than
50% luminal diameter on coronary angiography.
Patients with patent coronaries were enrolled as
controls. In subgroup analysis of CAD patients,
those with significant stenoses over two or more
coronary arteries were classified into multi-vessel
disease group, vs. patients with single-vessel dis-
ease. As this is a genetic association study, we re-
cruited both new onset MI and historical MI to
elucidate the genetic effect of this polymorphism
on MI risk in CAD patients. New onset MI was
defined according to the consensus criteria of ESC
and ACC.23 Historical MI that occurred before
the time of enrollment was verified by medical
record during hospitalization with the same cri-
teria. For patients with significant history of chest
pain, finding the pathologic Q wave on EKG or
fixed perfusion defect on stress and redistribution
thalium-201 myocardial perfusion scan, which is
compatible with angiographic findings, was also
defined as historical MI. Control patients who
did not meet the above criteria were classified as
having chronic stable angina.
Genotyping of CRP gene 1059 G>C
polymorphism and measurement of 
plasma CRP concentration
Blood was withdrawn after hospitalization, 
centrifuged, DNA extraction was performed with
standard phenol–chloroform method, and plasma
was stored in a −80°C freezer before analysis. Geno-
typing of CRP gene 1059 G/C polymorphism was
performed by polymerase chain reaction (PCR)
and further digestion by MaeIII restriction en-
zyme, as previously described.24–26 Briefly, PCR
was performed by using the following primers:
Forward-5′GATCTGTGTGATCTGAGAAACCTCT-
3′ and Reverse-5′GAGGTACCAGAGACAGAGAC-
GTG-3′. Target DNA was amplified using 94°C
for 5 minutes, then 30 cycles of 94°C for 30 sec-
onds, 57°C for 30 seconds and 72°C for 30 sec-
onds, followed by an extension step of 72°C for
10 minutes. Two percent agarose gel was used for
visualization. Quality control for the experiments
was evaluated by re-genotyping of 20 random
samples blinded to the technician.
Plasma CRP concentration was measured by
a high sensitivity immunonephelometry (Neph-
elometry, Behring Nephelometer II, Dade Behring
Marburg GmbH, Germany) with the lowest de-
tection limit of 0.16 mg/L. All laboratory analy-
ses were performed blinded with respect to the
diagnosis and patients’ characteristics.
Statistical analyses
Baseline differences between cases and controls
were compared by two-sample Student’s t test and
χ2 test for continuous and categorical variables,
respectively. Different genetic models were created
to investigate the genotype distribution between
cases and controls, including additive, dominant
and recessive. We applied multiple logistic regres-
sion to adjust for age, sex, proportions of diabetes,
hypertension, hypercholesterolemia, hypertrigly-
ceridemia and smoking habit for each genetic
model.
Since plasma CRP concentration was not nor-
mally distributed, we used logarithmic transfor-
mation for normalization. Analysis of variance
was applied to evaluate the differences in plasma
CRP concentration among subjects with different
genotypes, stratified by sex and altogether. Two-
sample Student’s t test was used to compare the
differences in plasma CRP concentration between
cases and controls for different clinical pheno-
types. Then we created multiple regression models
to predict plasma CRP concentration, including
CRP gene 1059 C allele carrier, clinical phenotypes
of CAD, age, sex, obesity (BMI ≥ 25 kg/m2) and
the aforementioned covariates. Statistical analyses
were performed with Stata version 8.0. All tests are
two-sided and p values less than 0.05 were con-
sidered statistically significant.
Results
A total of 365 cases (CAD) and 171 controls
(patent coronaries) were recruited in our associa-
tion study. The demographic characteristics are
shown in Table 1. Cases and controls differed
significantly in all conventional risk factors for
CAD, including diabetes, hypertension, hypercho-
lesterolemia, hypertriglyceridemia and smoking.
The allele frequency of G and C in our population
was 89.3% and 10.7%, respectively, similar to
those reported in Caucasian population.19 The
overall genotype distribution of CRP 1059 G > C
polymorphism in our study population was in
Hardy–Weinberg equilibrium.
Genotype data were analyzed under three 
genetic models: additive, dominant and recessive,
to increase the possibility for detecting an associ-
ation. Table 2 shows the genotype distributions
between cases and controls. There was no signifi-
cant association between CRP gene 1059 G > C
polymorphism and CAD in all genetic models.
In the subgroup analysis of patients with CAD,
CRP gene 1059 G > C polymorphism was neither
associated with MI nor multi-vessel disease when
compared to subjects with chronic stable angina
or single-vessel disease, respectively.
The results of plasma CRP concentration
among different genotypes of CRP gene 1059
G > C polymorphisms are shown in the Figure.
Subjects with CC and GC genotypes had signifi-
cantly lower plasma CRP concentration than those
with GG genotype (GG: 6.5 ± 5.8; GC: 3.3 ± 4.4;
CC: 2.3 ± 3.1 mg/L; p = 0.02). No significant dif-
ference in plasma CRP concentration was noted
between men and women for all genotypes. Table 3
shows that the mean plasma CRP concentration
CRP 1059 G > C polymorphism and its plasma level
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in cases was significantly higher than those in con-
trols for phenotypes of CAD vs. patent coronaries
(8.9±18.9 vs. 3.3±7.2mg/L, respectively, p<0.001)
and for MI vs. chronic stable angina (13.5 ± 22.9
vs. 5.2 ± 14.1 mg/L, respectively, p < 0.001). How-
ever, the mean plasma CRP concentration was
not significantly different between subjects with
multi-vessel disease and those with single-vessel
disease (9.7 ± 20.6 vs. 7.1 ± 14.4 mg/L, respectively,
p = 0.12).
To evaluate the predictors of plasma CRP con-
centration, we created a multiple regression model
as shown in Table 4. The independent predictors
for plasma CRP concentration were CRP gene
1059 C allele carriers (β = −0.53, p = 0.004), CAD
(β = 0.39, p = 0.02), age (β = 0.02, p = 0.001) and
the presence of diabetes (β = 0.4, p = 0.006). This
model indicates that CRP 1059 C allele carrier is
associated with lower plasma CRP concentration,
while at an older age, the presence of CAD or 
diabetes is associated with higher plasma CRP
concentration. All other covariates did not inde-
pendently affect plasma CRP concentration.
Discussion
The critical roles of CRP in cardiovascular disease
have made genetic studies of CRP an important
issue. In this study, we investigated the associa-
tion between CRP 1059 G > C polymorphism
and the prevalence of CAD in the Chinese popu-
lation in Taiwan. The CRP gene 1059 G > C poly-
morphism was neither associated with CAD nor
MI after adjustment for covariates, although this
polymorphism significantly affected plasma CRP
concentration. We also demonstrated that sub-
jects with CAD or MI had significantly higher
plasma CRP concentration compared to controls.
To the best of our knowledge, this is the first study
to evaluate the association between CRP 1059
G > C polymorphism and CAD. Zee and Ridker19
reported in prospective studies of Caucasian
populations that the CRP gene 1059 G > C poly-
morphism, despite affecting plasma CRP concen-
tration, was neither associated with future MI and
stroke events, nor with post-angioplasty restenosis.
On the contrary, a recent study by Chen et al27 in
a Chinese population revealed that the −717A > G
polymorphism in the promoter region of CRP
was associated with CAD, but they failed to show
the functional effect of the polymorphism on
plasma CRP concentration.
The concomitant correlation of plasma CRP
concentration with the CRP genotype and the
phenotype of CAD but the absence of associa-
tion between this CRP gene 1059 G > C polymor-
phism and CAD in our study may provide some
D.F. Dai, et al
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Table 1. Baseline characteristics of cases and controls
Patent coronaries CAD
p
(n = 171) (n = 365)
Age (yr) 60.9 ± 12.3 62.0 ± 11.5 0.3
Men, n (%) 94 (55) 228 (62.5) 0.1
BMI, kg/m2 25.3 ± 4.3 25.0 ± 4.0 0.44
TC, mg/dL 197.8 ± 42.7 219.8 ± 99.9 0.007
TG, mg/dL 162.6 ± 122.8 192.9 ± 121.8 0.008
Risk factors, n (%)
Diabetes 28 (16.4) 144 (39.4) < 0.001
Hypertension 92 (53.8) 252 (69.0) < 0.001
Smoking 59 (34.5) 166 (45.5) < 0.001
Hypercholesterolemia 72 (42.1) 237 (64.9) < 0.001
Hypertriglyceridemia 38 (22.2) 132 (36.2) 0.001
CAD = coronary artery disease; BMI = body mass index; TC = total cholesterol; TG = triglycerides.
argument that elevated plasma CRP level in CAD
is merely an epiphenomenon. It implies that CRP
is probably a surrogate marker in cardiovascular
disease. However, this explanation is less likely
due to increasing evidence of direct pathogenic
effects of CRP on atherogenesis. CRP may cause
the reduction of eNOS expression, inhibition of
angiogenesis and attenuation of endothelial pro-
genitor cell survival and may induce proinflam-
matory and proatherogenic effects in several types
of cells.11–18
Besides, we proposed another explanation for
this discrepancy. Other genetic and environmen-
tal factors also influence plasma concentration
of CRP. According to the results of the NHLBI
Family Heart Study, the heritability of CRP was
35–40%.28 This fact implies that acquired factors
are at least of the same importance as genetic 
factors in the determination of plasma CRP con-
centration. From the genetic perspectives, polymor-
phisms in the IL-1 gene cluster,29,30 IL-6,31 tumor
necrosis factor alpha32 and CRP genes19–21,33 were
shown to affect the expression of CRP. Since the
1059 G > C polymorphism is a silent mutation in
exon 2 of the CRP gene,24 its impact on plasma
CRP concentration may be due to linkage dise-
quilibrium with nearby genetic polymorphisms,
especially with those in the promoter region.33
CRP 1059 G > C polymorphism and its plasma level
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Figure. Mean plasma C-reactive protein (CRP) concentra-
tion stratified by CRP 1059 G > C polymorphism for both
men and women. GC and CC genotypes have significantly
lower plasma CRP concentration than GG genotype (*p <
0.05). No significant difference was noted between men
and women for all genotypes.
The other possible mechanism is the 1059 G > C
polymorphism affecting the stability of CRP
mRNA and hence changing the plasma CRP con-
centration. However, additional studies are needed
to clarify the exact mechanism. From the environ-
mental viewpoints, previous studies have indi-
cated several acquired factors that influenced
plasma CRP concentration, such as smoking, obe-
sity, diet and chronic infection. Our regression
model showed that the independent predictors of
plasma CRP concentration are age, CRP gene 1059
C allele and the presence of diabetes and CAD.
As our study revealed negative findings, the
issue of statistical power to address the research
questions is very crucial. Based on the size of our
study, we can detect, with 80% probability, at an
alpha error of 0.05, an odds ratio of greater than
1.8 for an association between CRP1059 allele C
and CAD, assuming an additive model. The lim-
itation of this study is that our controls were cho-
sen from subjects receiving coronary angiography
who may not reflect the condition of the general
population. Meantime, coronary angiography re-
mains a gold standard in the diagnosis of CAD.
The application of coronary angiography for all
participants may avoid the misclassification of
asymptomatic CAD or MI subjects, which has a
prevalence of 18–40%, depending on the popu-
lation studied.34,35 The other advantage of our
study is the homogeneous ethnicity of the Chinese
population in Taiwan, which makes it suitable
for genetic analysis.
On the other hand, one of the limitations was
that we did not recruit truly normal people and
analyze their CRP polymorphism. The control
group in this study was a combination of normal
subjects, patients with syndrome X, and patients
with insignificant coronary lesions. It would be
of interest to separate these heterogeneous groups
and observe the differences. In addition, the re-
gression model in this study might not be suffi-
cient to demonstrate the influence and interactions
D.F. Dai, et al
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Table 3. Mean plasma C-reactive protein (CRP) concentration in cases versus control
n Mean hs-CRP (mg/L) p
CAD 365 8.9 ± 18.9 < 0.001
Patent 171 3.3 ± 7.2
MI 163 13.5 ± 22.9 < 0.001
CSA 202 5.2 ± 14.1
Multi-vessel disease 258 9.7 ± 20.6 0.12
Single-vessel disease 107 7.1 ± 14.4
CAD = coronary artery disease; MI = myocardial infarction; CSA = chronic stable angina.
Table 4. Multiple regression model to predict plasma C-reactive protein (CRP) concentration (log transformed)
β p 95% CI
CRP1059 C carrier (vs. non-carrier) −0.53 0.004 −0.89, −0.18
Coronary artery disease 0.39 0.02 0.08, 0.70
Age, yr 0.02 0.001 0.01, 0.03
Male (vs. female) 0.32 0.25 −0.20, 0.73
Diabetes 0.40 0.006 0.12, 0.69
Hypertension 0.01 0.93 −0.26, 0.29
Obesity 0.13 0.35 −0.15, 0.41
Smoking 0.15 0.33 −0.15, 0.44
Hypercholesterolemia −0.24 0.09 −0.51, 0.03
Hypertriglyceridemia 0.10 0.49 −0.19, 0.40
among a series of genetic and non-genetic factors.
Our future goal will target at designing a decision
tool to analyze these potential confounders as a
whole.
In conclusion, our data suggest that human
CRP gene 1059 G > C polymorphism is associated
with plasma CRP concentration in the Chinese
who live in Taiwan who receive coronary angiog-
raphy. Higher plasma CRP concentration is also
significantly correlated with CAD and MI. How-
ever, to better understand the contribution of ge-
netic profiles vs. environmental effects on plasma
CRP concentration and the risk of cardiovascular
disease, further research of CRP together with re-
lated inflammatory genes, and by the applica-
tion of haplotype analysis, intergenic interaction
and gene–environment interaction analysis are
necessary.
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